A new review considers how SGLT2 inhibitors like dapagliflozin and empagliflozin have been shown to clinically improve gout while reducing its cardiometabolic and renal comorbidities.
Sodium-glucose cotransporter-2 inhibitors are not approved to treat gout, lupus, or lupus nephritis, but clinicians are uncovering signs of benefits in these conditions.